Hancock Jaffe Laboratories (NASDAQ:HJLI) Given Buy Rating at Maxim Group

Maxim Group reiterated their buy rating on shares of Hancock Jaffe Laboratories (NASDAQ:HJLI) in a report published on Wednesday, AnalystRatings.com reports. The brokerage currently has a $3.00 price target on the stock.

Separately, ValuEngine downgraded Hancock Jaffe Laboratories from a buy rating to a hold rating in a research note on Thursday, September 26th.

Shares of HJLI stock traded down $0.02 during trading hours on Wednesday, reaching $0.52. The company had a trading volume of 24,000 shares, compared to its average volume of 135,153. The company has a 50 day moving average of $0.69 and a 200 day moving average of $1.11. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.46 and a current ratio of 1.52. Hancock Jaffe Laboratories has a 1-year low of $0.44 and a 1-year high of $3.45.

Hancock Jaffe Laboratories (NASDAQ:HJLI) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.04. Hancock Jaffe Laboratories had a negative return on equity of 224.86% and a negative net margin of 5,293.30%.

A hedge fund recently bought a new stake in Hancock Jaffe Laboratories stock. Jane Street Group LLC purchased a new stake in Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 77,915 shares of the company’s stock, valued at approximately $81,000. Jane Street Group LLC owned 0.43% of Hancock Jaffe Laboratories as of its most recent SEC filing. Hedge funds and other institutional investors own 1.30% of the company’s stock.

About Hancock Jaffe Laboratories

Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.

Featured Story: Call Option

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.